- ISIN
- US76029N1063
- CUSIP
- 76029N106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 20, 2018
Highlights
- Market Cap
- $1.03B
- Enterprise Value
- $940.50M
- EPS (TTM)
- -$3.43
- Gross Profit (TTM)
- -$2.49M
- EBITDA (TTM)
- -$315.29M
- Year Range
- $1.50 - $13.24
- Target Price
- $13.67
- ROA (TTM)
- -94.38%
- ROE (TTM)
- -149.55%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
REPL Performance Chart
Replimune Group, Inc. (REPL) is up 15.0% since the beginning of the year. At $11 per share, REPL is trading 15.6% below its 52-week high of $13. Investors who bought $1,000 worth of REPL shares 5 years ago would now be looking at an investment worth $310.
Loading charts...
Returns By Period
Replimune Group, Inc. (REPL) has returned 15.02% so far this year and 20.60% over the past 12 months.
Replimune Group, Inc.
- 1D
- 9.72%
- 1M
- 127.70%
- YTD
- 15.02%
- 6M
- 12.59%
- 1Y
- 20.60%
- 3Y*
- -22.30%
- 5Y*
- -20.87%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
REPL Monthly Returns History
Based on dividend-adjusted daily data since Jul 20, 2018, REPL's average daily return is +0.22%, while the average monthly return is +3.79%. At this rate, an investment would double in approximately 1.6 years.
Historically, 47% of months were positive and 53% were negative. The best month was May 2026 with a return of +238.1%, while the worst month was Apr 2026 at -66.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.
On a daily basis, REPL closed higher 49% of trading days. The best single day was Jul 30, 2025 with a return of +101.3%, while the worst single day was Jul 22, 2025 at -77.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -27.67% | 8.82% | 0.00% | -66.41% | 238.13% | 28.65% | 15.02% | ||||||
| 2025 | 15.44% | -9.30% | -23.11% | 0.31% | -8.18% | 3.45% | -24.33% | -23.19% | -22.41% | 132.22% | 2.77% | -2.80% | -19.74% |
| 2024 | -7.95% | 10.57% | -4.78% | -22.28% | -17.01% | 70.78% | 11.11% | 1.70% | 7.77% | 7.30% | 19.73% | -13.99% | 43.65% |
| 2023 | 2.39% | -21.36% | -19.36% | -5.27% | 13.51% | 22.27% | -9.26% | -3.08% | -16.21% | -14.85% | -23.27% | -24.60% | -69.01% |
| 2022 | -26.83% | -19.11% | 5.86% | -1.24% | -13.36% | 20.30% | 10.30% | -1.14% | -9.39% | 6.31% | 11.49% | 32.88% | 0.37% |
| 2021 | 1.70% | -10.75% | -11.90% | 19.93% | 6.50% | -1.41% | -14.81% | -2.96% | -6.68% | -0.44% | -3.46% | -4.88% | -28.96% |
Benchmark Metrics
Replimune Group, Inc. has an annualized alpha of 46.95%, beta of 1.15, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since July 20, 2018.
- This stock participated in 135.81% of S&P 500 Index downside but only 72.27% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 46.95%
- Beta
- 1.15
- R²
- 0.04
- Upside Capture
- 72.27%
- Downside Capture
- 135.81%
Return for Risk
Risk / Return Rank
REPL ranks 62 for risk / return — better than 62% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Replimune Group, Inc. (REPL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REPL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.94 | ||
| Sortino ratioReturn per unit of downside risk | -0.47 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.37 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 0.24 | 2.78 | -2.55 |
| Martin ratioReturn relative to average drawdown | 0.44 | 12.44 | -12.00 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Replimune Group, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Replimune Group, Inc. was 96.77%, occurring on Apr 13, 2026. The portfolio has not yet recovered.
The current Replimune Group, Inc. drawdown is 78.77%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -96.77%Apr 2026 | 5y 4mo | — | 5y 6moDec 2020 - now |
COVID crash2020 | -59.80%Mar 2020 | 1y 6mo | 2mo 13d | 1y 9moSep 2018 - Jun 2020 |
2020 bear market2020 | -27.36%Jul 2020 | 1mo 2d | 1mo 1d | 2mo 3dJun 2020 - Aug 2020 |
2020 bear market2020 | -23.56%Sep 2020 | 23d | 20d | 1mo 13dSep 2020 - Oct 2020 |
2020 correction2020 | -15.89%Jun 2020 | 0s | 16d | 16dJun 2020 - Jun 2020 |
Drawdown Indicators
| REPL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.77% | -56.78% | -39.99% |
Max Drawdown (1Y)Largest decline over 1 year | -86.54% | -9.10% | -77.44% |
Max Drawdown (3Y)Largest decline over 3 years | -92.87% | -18.90% | -73.97% |
Max Drawdown (5Y)Largest decline over 5 years | -95.70% | -25.43% | -70.27% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -78.77% | -1.80% | -76.97% |
Average DrawdownAverage peak-to-trough decline | -55.68% | -10.71% | -44.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.41% | 2.03% | +45.38% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Replimune Group, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Replimune Group, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for REPL in comparison with other companies in the Biotechnology industry. Currently, REPL has a P/B value of 4.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with REPL
Add Replimune Group, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with REPL